老年局部晚期胃癌放疗作用初步研究

doi:10.3760/cma.j.issn.1004-4221.2017.01.009

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (787 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract

Objective To compare the efficacy and resistance between S-1 combined with radiotherapy and S-1 alone in the treatment of elderly patients with locally advanced gastric cancer. Methods Fifty-eight elderly patients with unresectable locally advanced (stage Ⅲ) gastric cancer were randomly and equally divided into S-1 combined with concurrent radiotherapy group (experimental group) and S-1 alone group (control group). The experimental group received 4 cycles of S-1 treatment with each cycle containing two-week oral administration of S-1 at a dose of 40 mg/m² twice a day followed by one-week drug withdrawal. Gastric intensity-modulated radiotherapy was performed concurrently with a dose of 45 Gy (1.8 Gy per fraction). The control group received the same dose of S-1 alone. Short-term outcomes and adverse reactions were evaluated in the two groups. Comparison was made by chi-square test. Results All patients completed the planning treatment. The experimental group had significantly higher objective response, disease control, and symptom remission rates than the control group (52% vs. 24%, P=0.03;76% vs. 45%, P=0.016;86% vs. 48%, P=0.005). There were no significant differences in the incidence of nausea and vomiting, anorexia, leukopenia, diarrhea, or thrombocytopenia between the two groups (all P>0.05). Conclusions S-1 treatment combined with concurrent radiotherapy improves the short-term outcomes and causes tolerable toxicities in the treatment of elderly patients with locally advanced gastric cancer.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Li Jingxia
	Mu Shuangfeng
	Wang Xiaohong
	Mu Lixiang

Key words： Gastric neoplasms/intensity-modulated radiotherapy Gastric neoplasms/chemotherapy Treatment outcome

Received: 09 May 2016

Cite this article:

Li Jingxia,Mu Shuangfeng,Wang Xiaohong et al. The role of radiation therapy in the treatment of elderly patients with locally advanced gastric cancer[J]. Chinese Journal of Radiation Oncology, 2017, 26(1): 41-44.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2017.01.009 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2017/V26/I1/41

[1] 郝捷,陈万青.中国肿瘤登记年报[M].北京:军事医学科学出版社,2012.
He J,Chen WQ.China cancer registry annual report[M].Beijing:Military Medical Science Press,2012.
[2] 杨焱,穆庆霞,张胜,等.S-1化疗同步调强放疗治疗老年局部晚期胃癌的近期疗效[J].江苏医药,2013,39(24):3008-3009.
Yan Y,Mu QX,Zhang S,et al. Short term efficacy of S-1 chemotherapy with concurrent intensity modulated radiation therapy for elderly patients with locally advanced gastric cancer[J].Jiangsu Med J,2013,39(24):3008-3009.
[3] 王鑫,金晶.替吉奥在胃癌化放疗中的应用[J].中华放射肿瘤学杂志,2015,24(2):204-208.DOI:10.3760/cma.j.issn.1004-4221.2015.02.024.
Wang X,Jin J.S-1 in gastric cancer application in radiotherapy[J].Chin J Radiat Oncol,2015,24(2):204-208.DOI:10.3760/cma.j.issn.1004-4221.2015.02.024.
[4] 李小奇,姜雷,赵达,等.胃癌术后放化疗与单纯化疗随机对照试验结果的荟萃分析[J].中华放射肿瘤学杂志,2014,23(1):1-4.DOI:10.3760/cma.j.issn.1004-4221.2014.01.001.
Li XQ,Jiang L,Zhao D,et al. Randomized controlled trials of postoperative chemoradiotherapy versus chemotherapy alone in patients with gastric cancer:a meta-analysis[J].Chin J Radiat Oncol,2014,23(1):1-4.DOI:10.3760/cma.j.issn.1004-4221.2014.01.001.
[5] Edge SB,Byrd DR,Compton CC,et al. AJCC cancer staging manual[M].7th ed. New York:Springer,2010.
[6] Eisenhauer EA,Therasse P,Bogaerts J,et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009,45(2):228-247.DOI:10.1016/j.ejca.2008.10.026.
[7] 赵金朋,冯锦,谢海彬,等.胃癌手术患者2338例临床病理特征分析[J].江苏医药,2015,41(1):41-44.
Zhao JP,Feng J,Xie HB,et al. Analysis of clinicopathologic features of 2 338 patients with gastric cancer underwent operation[J].Jiangsu Med J,2015,41(1):41-44.
[8] 储大同.当代肿瘤内科治疗方案评价[M].3版.北京:人民卫生出版社,2010:158.
Chu DT.Evaluation of current medical treatment program for cancer[M].3 ed. Beijing:People's Medical Publishing House,2010:158
[9] Al-Batran SE,Hartmann JT,Probst S,et al. Phase Ⅲ trial in metastatic gastroesophageal adenocarcinoma with fluorouracil,leucovorin plus either oxaliplatin or cisplatin:a study of the Arbeitsgemeinschaft Internistische Onkologie[J].J Clin Oncol,2008,26(9):1435-1442.DOI:10.1200/JCO.2007.13.9378.
[10] Van Cutsem E,Moiseyenko VM,Tjulandin S,et al. Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V₃₂₅ Study Group[J].J Clin Oncol,2006,24(31):4991-4997.DOI:10.1200/JCO.2006.06.8429.
[11] Koizumi W,Narahara H,Hara T,et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial):a phase Ⅲ trial[J].Lancet Oncol,2008,9(3):215-221.DOI:10.1016/S1470-2045(08)70035-4.
[12] Ajani JA,Rodriguez W,Bodoky G,et al. Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study:the FLAGS trial[J].J Clin Oncol,2010,28(9):1547-1553.DOI:10.1200/JCO.2009.25.4706.
[13] 张星霖,贾伟丽.替吉奥胶囊治疗老年晚期胃癌的临床观察[J].现代肿瘤医学,2011,19(6):1189-1190.DOI:10.3969/j.issn.1672-4992.2011.06.48.
Zhang XL,Jia WL.Clinical study of S1 capsule in the treatment of elderly patients with advanced gastric cancer[J].J Mod Oncol,2011,19(6):1189-1190.DOI:10.3969/j.issn.1672-4992.2011.06.48.
[14] 邹卉瑜,陈笑艳,张逸凡,等.替吉奥胶囊(S-1)在中国癌症患者体内的药代动力学和生物等效性[J].中国临床药理学杂志,2010,26(5):349-354.DOI:10.3969/j.issn.1001-6821.2010.05.008.
Zou HY,Chen XY,Zhang YF,et al. Pharmacokinetics and bioequivalence of S-1 capsules in Chinese patients with cancer[J].Chin J Clin Pharmacol,2010,26(5):349-354.DOI:10.3969/j.issn.1001-6821.2010.05.008.
[15] 孙燕.内科肿瘤学[M].北京:人民卫生出版社,2001:387-388.Sun Y.Medical oncology[M].Beijing:People's Medical Publishing House,2001:387-388.
[16] 殷蔚伯,余子豪,徐国镇,等.肿瘤放疗学[M].4版.北京:中国协和医科大学出版社,2008:237-239.
Yin WB,Yu ZH,Xu GZ,et al. Radiation oncology[M].4 ed. Beijing:Pecking Union Medical College Press,2008:237-239.
[17] 郭晓光.替吉奥单药治疗老年晚期胃癌的临床观察[J].内蒙古医学杂志,2015,47(1):45-47.DOI:10.16096/J.cnki.nmgyxzz.2015.47.01.015.
Guo XG.Clinical observation of S-1 in the treatment of elderly patients with advanced gastric cancer[J].Inner Mongolia Med J,2015,47(1):45-47.DOI:10.16096/J.cnki.nmgyxzz.2015.47.01.015.
[18] Milano MT,Garofalo MC,Chmura SJ,et al. Intensity-modulated radiation therapy in the treatment of gastric cancer:early clinical outcome and dosimetric comparison with conventional techniques[J].Br J Radiol,2006,79(942):497-503.DOI:10.1259/bjr/43441736.
[19] Minn AY,Hsu A,La T,et al. Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer[J].Cancer,2010,116(16):3943-3952.DOI:10.1002/cncr.25246.
[20] Chakravarty T,Crane CH,Ajani JA,et al. Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma[J].Int J Radiat Oncol Biol Phys,2012,83(2):581-586.DOI:10.1016/j.ijrobp.2011.07.035.
[21] Boda-Heggemann J,Weiss C,Schneider V,et al. Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall-and disease-free survival in advanced gastric cancer[J].Strahlenther Onkol,2013,189(5):417-423.DOI:10.1007/s00066-013-0309-2.
[22] Liu GF,Bair RJ,Bair E,et al. Clinical outcomes for gastric cancer following adjuvant chemoradiation utilizing intensity modulated versus three-dimensional conformal radiotherapy[J].PLoS One,2014,9(1):e82642.DOI:10.1371/journal.pone.0082642.
[23] 王鑫,金晶.晚期胃癌的姑息性放疗价值研究回顾[J].中华放射肿瘤学杂志,2016,25(1):85-89.DOI:10.3760/cma.j.issn.1004-4221.2016.01.021.
Wang X,Jin J.Research progress in palliative radiotherapy for advanced gastric cancer[J].Chin J Radiat Oncol,2016,25(1):85-89.DOI:10.3760/cma.j.issn.1004-4221.2016.01.021.
[24] Moertel CG,Reitemeier RJ,Childs DJ,et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer[J].Lancet,1969,294(7626):865-867.DOI:10.1016/S0140-6736(69)92326-5.
[25] Yuan ST,Wang FL,Liu N,et al. Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence[J].Am J Clin Oncol,2015,38(2):130-134.DOI:10.1097/COC.0b013e31828f5cb6.
[26] Hazard L,O'Connor J,Scaife C.Role of radiation therapy in gastric adenocarcinoma[J].World J Gastroenterol,2006,12(10):1511-1520.DOI:10.3748/wjg.v12.i10.1511.